Guggenheim Capital LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,039 shares of the company’s stock after selling 55,865 shares during the quarter. Guggenheim Capital LLC owned about 0.40% of IDEXX Laboratories worth $66,612,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC purchased a new position in IDEXX Laboratories during the first quarter valued at $105,000. Three Peaks Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the 1st quarter worth $108,000. Optimum Investment Advisors purchased a new position in shares of IDEXX Laboratories in the 1st quarter worth $139,000. Financial Gravity Wealth Inc. bought a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $191,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $191,000. Institutional investors and hedge funds own 86.28% of the company’s stock.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, June 15th. BidaskClub upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. ValuEngine upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Credit Suisse Group lifted their price objective on shares of IDEXX Laboratories from $228.00 to $231.00 and gave the stock an “outperform” rating in a research report on Thursday, June 21st. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. IDEXX Laboratories currently has a consensus rating of “Buy” and an average target price of $222.43.
IDEXX Laboratories opened at $217.94 on Friday, MarketBeat Ratings reports. The company has a quick ratio of 0.72, a current ratio of 0.96 and a debt-to-equity ratio of -12.43. The firm has a market cap of $18.89 billion, a PE ratio of 66.45, a price-to-earnings-growth ratio of 2.58 and a beta of 0.64. IDEXX Laboratories, Inc. has a 52-week low of $146.09 and a 52-week high of $229.01.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Friday, May 4th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.09. The business had revenue of $537.60 million for the quarter, compared to analysts’ expectations of $525.14 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The business’s quarterly revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 earnings per share. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.17 EPS for the current fiscal year.
In related news, Director William T. End sold 9,470 shares of IDEXX Laboratories stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $208.36, for a total value of $1,973,169.20. Following the transaction, the director now directly owns 31,786 shares in the company, valued at approximately $6,622,930.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Giovani Twigge sold 1,626 shares of IDEXX Laboratories stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $204.37, for a total value of $332,305.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,571 shares of company stock worth $2,405,215. 2.56% of the stock is owned by corporate insiders.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.